Bayer subsidiary doses first patient with Parkinson’s disease cell therapy
German pharma company announces progress in its ‘two-pronged’ cell and gene therapy approach to Parkinson’s disease
Read More
Tag: BlueRock Therapeutics
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
- R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
